Mass screening for early detection of renal disease: Benefits and limitations of self-testing for proteinuria

Journal of Nephrology

Volumn 22, Issue 2, 2009, Pages 249-254

  Heidland, August ^a   Bahner, Udo ^b   Deetjen, Annette ^c   Götz, Rüdiger ^d   Heidbreder, Ekkehart ^a   Schäfer, Roland ^e   Teschner, Markus ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b KfH Kidney Centre   (Germany)

^c Physician in Private Practice   (Austria)

^d Dialysis Centre   (Germany)

^e UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Chronic kidney disease; Dipsticks; Mass screening; Self testing

Indexed keywords

ARTICLE; DIABETIC NEPHROPATHY; DIPSTICK TEST; EARLY DIAGNOSIS; ESSENTIAL HYPERTENSION; FALSE POSITIVE RESULT; FEMALE; GERMANY; GLOMERULONEPHRITIS; HUMAN; KIDNEY CARCINOMA; KIDNEY DISEASE; KIDNEY POLYCYSTIC DISEASE; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; NEPHROLITHIASIS; PROTEINURIA; PYELONEPHRITIS; SELF EVALUATION; URINALYSIS; ADOLESCENT; ADULT; AGED; CHILD; COMPARATIVE STUDY; METHODOLOGY; MIDDLE AGED; PATIENT COMPLIANCE; PREVALENCE; REPRODUCIBILITY; TIME; URBAN POPULATION; URINE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; FEMALE; GERMANY; HUMANS; KIDNEY DISEASES; MALE; MASS SCREENING; MIDDLE AGED; PATIENT COMPLIANCE; PREVALENCE; PROTEINURIA; REPRODUCIBILITY OF RESULTS; TIME FACTORS; URBAN POPULATION; URINALYSIS; YOUNG ADULT;

EID: 67649396085     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41: 1-12.
2. Jones CA, Francis ME, Eberhardt MS, et al. Microalbuminuria in the US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2002; 39: 445-459.
3. Wakai K, Nakai S, Kikushi K, et al. Trends in incidence of end-stage renal disease in Japan, 1983-2000: age-adjusted and age-specific rates by gender and cause. Nephrol Dial Transplant 2004; 16: 2044-2052.
4. US Renal Data System. Excerpts from USRDS 2001 annual data report: atlas of end-stage renal disease in the United States. Am J Kidney Dis 2001; 38(Suppl 3): S1-S248.
5. Lysaght MJ. Maintenance dialysis population dynamics: current trends and long-term implications. J Am Soc Nephrol 2002; 13(Suppl 1): S37-S40.
6. Grassmann A, Gioberge S, Moeller S, Brown G. End-stage renal disease: global demographics in 2005 and observed trends. Artif Organs 2006; 30: 895-897.
7. Xue JL, Ma JZ, Louis TA, Collins AJ. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol 2001; 12: 2753-2758.
8. US Renal Data System. Excerpts from USRDS 2007 annual data report: 2007. American Journal of Kidney Disease 2008; 51:S1-S320. (Chapter "Incident & Prevalence of ESRD: S81-S98)
9. Nakai S, Masakane I, Akiba T, et al. An overview of dialysis treatment in Japan (as of 31 December 2006). JSDT Journal 2008; 41: 1-28.
10. Quasi-Niere-Report [article in German]. Jahresbericht. 2005/2006. http://www.bundesverband-niere.de/files/QuaSi-Niere-Bericht_2005-2006.pdf
11. Kannel WB, Stampfer MJ, Castelli WP, Verter J. The prognostic significance of proteinuria: the Framingham Study. Am Heart J 1984; 108: 1347-1352.
12. Vanholder R, Massy Z, Argiles A, et al. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005; 20: 1048-1056.
13. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
14. Kiberd BA, Clase CM. Cumulative risk for the developing end-stage renal disease in the US population. J Am Soc Nephrol 2002; 13: 1635-1644.
15. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-1462.
16. Brenner BM, Cooper ME, de Zeeuw D, et al; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
17. Asselsbergs FW, Diercks GFH, Hillege HL, et al; Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation. 2004; 110: 2809-2816.
18. Coresh J, Byrd-Holt D, Astor BC, et al. Chronic kidney disease awareness, prevalence, and trends among US adults. J Am Soc Nephrol 2005; 16: 180-188.
19. Nickolas TL, Frisch GD, Opotowsky AR, Arons R, Radhakrishnan J. Awareness of kidney disease in the US population: findings from the National Health and Nutrition Examination Survey (NHANES) 1999 to 2000. Am J Kidney Dis 2004; 44: 185-197.
20. Iseki K, Iseki C, Ikemiya Y, Fukiyama K. Risk of developing end-stage renal disease in a cohort of mass screening. Kidney Int 1996; 49: 800-805.
21. Iseki K, Yoshiharu I, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int 2003; 63: 1468-1474.
22. Iseki K. Screening for renal disease: what can be learned from the Okinawa experience. Nephrol Dial Transplant 2006; 21: 839-843.
23. Hillege HL, Fidler V, Diercks GF, et al; Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and non-cardiovascular mortality in general population. Circulation 2002; 606: 1777-1782.
24. Verhave JC, Gansevoort RT, Hillege HL, et al; PREVEND Study Group. An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. Kidney Int 2004; (Suppl 92): S18-S21.
25. De Jong PE, Curhan GC. Sreening, monitoring, and treatment of albuminuria: public health perspectives. J Am Soc Nephrol 2006; 17: 2120-2126.
26. Eknoyan G, Hostetter T, Bakris GL, et al. Proteinuria and other markers of chronic kidney disease: a position statement of the National Kidney Foundation (NKF) and the National Institute of Diabetes and Digestive and Kidney Disease (NIDDK). Am J Kidney Dis 2003; 42: 617-622.
27. Ginsberg JM, Chang BS, Matarese RA, et al. Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med 1983; 309: 1543-1546.
28. Davidson MB, Smiley JF. Relationship between dipstick positive proteinuria and albumin:creatinine ratios. J Diabetes Complications 1999; 13: 52-55.
29. Halbesma N, Kuiken DS, Brantsma AH, et al. Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening. J Am Soc Nephrol 2006; 17: 2582-2590.
30. de Jong PE, Gansevoort RT, Bakker SJ. Macroalbuminuria and microalbuminuria: do both predict renal and cardiovascular events with similar strength? J Nephrol 2007; 20: 375-380.
31. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as a predictor of vascular disease in non-diabetic subjects. Lancet. 1988; 2: 530-533.
32. Stehouwer CD, Smulders YM. Microalbuminuria and risk for cardiovascular disease: analysis of potential mechanisms. J Am Soc Nephrol 2006; 17: 2106-2111.
33. Amann K, Wanner CH, Ritz E. Cross-talk between the kidney and the cardiovascular system. J Am Soc Nephrol 2006; 17: 2112-2119.
34. Constantiner M, Ashwini R, Sehgal R, et al. A dipstick protein and specific gravity algorithm accurately predicts pathological proteinuria. Am J Kidney Dis 2005; 45: 833-841.